** Drugmaker Amgen's AMGN.O shares fall 2.8% to $281 in extended trading
** Company says U.S. FDA placed a clinical hold on an early-stage study for its experimental weight-loss drug AMG 513
** Amgen says discussions are underway on a path forward to reopen the study
** Company posts Q4 adj profit of $5.31/shr vs analysts' average est. of $5.08/shr - LSEG
** Up to last close, stock down 10.2% in the last 12 months
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。